Integral Health Asset Management as of June 30, 2020
Portfolio Holdings for Integral Health Asset Management
Integral Health Asset Management holds 60 positions in its portfolio as reported in the June 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| LHC | 6.5 | $22M | 125k | 174.32 | |
| Quest Diagnostics Incorporated (DGX) | 4.1 | $14M | 120k | 113.96 | |
| Bristol Myers Squibb (BMY) | 3.5 | $12M | 200k | 58.80 | |
| Arena Pharmaceuticals Com New | 3.3 | $11M | 175k | 62.95 | |
| BioMarin Pharmaceutical (BMRN) | 3.0 | $9.9M | 80k | 123.34 | |
| Charles River Laboratories (CRL) | 2.9 | $9.6M | 55k | 174.35 | |
| Gw Pharmaceuticals Ads | 2.8 | $9.2M | 75k | 122.72 | |
| AmerisourceBergen (COR) | 2.7 | $9.1M | 90k | 100.77 | |
| Nevro (NVRO) | 2.7 | $9.0M | 75k | 119.47 | |
| Chemocentryx | 2.6 | $8.6M | 150k | 57.54 | |
| Blueprint Medicines (BPMC) | 2.6 | $8.6M | 110k | 78.00 | |
| Sage Therapeutics (SAGE) | 2.4 | $8.1M | 195k | 41.58 | |
| Agios Pharmaceuticals (AGIO) | 2.4 | $8.0M | 150k | 53.48 | |
| Cytokinetics Com New (CYTK) | 2.4 | $8.0M | 340k | 23.57 | |
| Danaher Corporation (DHR) | 2.4 | $8.0M | 45k | 176.82 | |
| Humana (HUM) | 2.3 | $7.8M | 20k | 387.75 | |
| Seattle Genetics | 2.3 | $7.6M | 45k | 169.91 | |
| Regeneron Pharmaceuticals (REGN) | 2.2 | $7.5M | 12k | 623.67 | |
| Catalent (CTLT) | 2.2 | $7.3M | 100k | 73.30 | |
| Molina Healthcare (MOH) | 2.1 | $7.1M | 40k | 177.97 | |
| NuVasive | 2.1 | $7.0M | 125k | 55.66 | |
| Astrazeneca Sponsored Adr (AZN) | 2.0 | $6.6M | 125k | 52.89 | |
| Dex (DXCM) | 1.8 | $6.1M | 15k | 405.40 | |
| Universal Hlth Svcs CL B (UHS) | 1.8 | $6.0M | 65k | 92.89 | |
| Amgen (AMGN) | 1.8 | $5.9M | 25k | 235.88 | |
| Merck & Co (MRK) | 1.7 | $5.8M | 75k | 77.33 | |
| Eli Lilly & Co. (LLY) | 1.7 | $5.7M | 35k | 164.17 | |
| Mirati Therapeutics | 1.7 | $5.7M | 50k | 114.18 | |
| Momenta Pharmaceuticals | 1.5 | $5.0M | 150k | 33.27 | |
| EXACT Sciences Corporation (EXAS) | 1.4 | $4.8M | 55k | 86.95 | |
| Abbott Laboratories (ABT) | 1.4 | $4.6M | 50k | 91.44 | |
| Horizon Therapeutics Pub SHS | 1.3 | $4.4M | 80k | 55.58 | |
| Baxter International (BAX) | 1.3 | $4.3M | 50k | 86.10 | |
| Zimmer Holdings (ZBH) | 1.3 | $4.2M | 35k | 119.37 | |
| McKesson Corporation (MCK) | 1.1 | $3.8M | 25k | 153.44 | |
| Envista Hldgs Corp (NVST) | 1.1 | $3.7M | 175k | 21.09 | |
| Halozyme Therapeutics (HALO) | 1.1 | $3.6M | 135k | 26.81 | |
| Exelixis (EXEL) | 1.1 | $3.6M | 150k | 23.74 | |
| Gossamer Bio (GOSS) | 1.1 | $3.5M | 270k | 13.00 | |
| Insulet Corporation (PODD) | 1.0 | $3.5M | 18k | 194.28 | |
| Akebia Therapeutics (AKBA) | 1.0 | $3.4M | 250k | 13.58 | |
| Moderna Put Put Option | 1.0 | $3.2M | 50k | 64.22 | |
| Denali Therapeutics (DNLI) | 0.9 | $3.1M | 130k | 24.18 | |
| PerkinElmer (RVTY) | 0.9 | $2.9M | 30k | 98.10 | |
| Change Healthcare | 0.8 | $2.8M | 250k | 11.20 | |
| Dicerna Pharmaceuticals | 0.8 | $2.8M | 110k | 25.40 | |
| Intra Cellular Therapies Call Call Option | 0.8 | $2.6M | 100k | 25.67 | |
| Abbvie (ABBV) | 0.7 | $2.5M | 25k | 98.20 | |
| Neurocrine Biosciences (NBIX) | 0.7 | $2.4M | 20k | 122.00 | |
| Zogenix Com New | 0.7 | $2.4M | 90k | 27.01 | |
| Amarin Corp Spons Adr New (AMRN) | 0.7 | $2.4M | 350k | 6.92 | |
| Fate Therapeutics (FATE) | 0.7 | $2.4M | 70k | 34.31 | |
| Macrogenics (MGNX) | 0.6 | $2.0M | 70k | 27.91 | |
| Beigene Sponsored Adr (BGNE) | 0.6 | $1.9M | 10k | 188.40 | |
| Walgreen Boots Alliance (WBA) | 0.5 | $1.7M | 40k | 42.40 | |
| Ptc Therapeutics I (PTCT) | 0.5 | $1.5M | 30k | 50.73 | |
| GenMark Diagnostics | 0.4 | $1.5M | 100k | 14.71 | |
| Karyopharm Therapeutics (KPTI) | 0.4 | $1.4M | 75k | 18.95 | |
| Incyte Corporation (INCY) | 0.3 | $1.0M | 10k | 104.00 | |
| Bristol-myers Squibb Right 99/99/9999 | 0.2 | $537k | 150k | 3.58 |
